Abstract 5112
Background
Most cancer patients are treated and followed up on an outpatient basis. A nursing led model of telephone care attention for cancer patients can be useful to improve the symptomatic control and the toxicity of the treatment. This model is being implemented in our hospital belonging to the Andorran Health Care Service. The specific aims of this study is to assess a nursing led model of telephone care attention for cancer patients in the course of treatment.
Methods
A descriptive prospective design has been used to analyze the telephone calls of cancer patients in treatment between outpatient appointments and the resolution capacity of oncology nurses. Telephone calls have been collected from October 2018 to March 2019 in a database. The variables analyzed using this database were: age, sex, type of tumor, type of treatment (oral or intravenous chemotherapy or immunotherapy), call reason and nursing resolution.
Results
49 telephone calls and 52 call reasons have been registered of 45 patients. On average, the patients were 58.1 (± 9.4) years old and 53% of them were male. Patients with colon and breast cancer were the most frequent, representing 20% and 16% respectively. 47% of patients were receiving intravenous chemotherapy, 36% oral chemotherapy and 18% immunotherapy. The call reasons were: 33% related to disease symptoms, 24 % related to toxicity, and 21 % related to treatment information and general issues. The most frequent reason for consultation was pain (23%) and the second was diarrhea (15%). Of the total telephone calls received, 92% were resolved by the nurse compared to 8% who required attention by a physician (p < 0.001).
Conclusions
Oncology nurse led model of telephone support for patients with cancer who attend outpatient treatment can improve symptomatic and toxicity management, reducing medical appointments and admissions to the Emergency Service.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Nostra Senyora de Meritxell.
Funding
Has not received any funding.
Disclosure
G. Simó: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. C. Royo: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Mahia: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Baillés: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Echevarria: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. A. Berenguer: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Albiol: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract